BioVaxys Technology (XCNQ:BIOV) Total Long-Term Liabilities : C$0.00 Mil (As of Jan. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. BioVaxys Technology's Total Long-Term Liabilities for the quarter that ended in Jan. 2025 was C$0.00 Mil.

BioVaxys Technology Total Long-Term Liabilities Historical Data

The historical data trend for BioVaxys Technology's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Total Long-Term Liabilities Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Total Long-Term Liabilities

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Total Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

BioVaxys Technology Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

BVAXF:USA 5LB:Germany

Address

595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Executives

James Passin	Director, Senior Officer
Kenneth Kovan	Senior Officer

BioVaxys Technology Headlines

No Headlines